183 related articles for article (PubMed ID: 16533784)
21. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Weingart J; Grossman SA; Carson KA; Fisher JD; Delaney SM; Rosenblum ML; Olivi A; Judy K; Tatter SB; Dolan ME
J Clin Oncol; 2007 Feb; 25(4):399-404. PubMed ID: 17264335
[TBL] [Abstract][Full Text] [Related]
22. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
[TBL] [Abstract][Full Text] [Related]
23. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Wedge SR; Porteous JK; Newlands ES
Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
[TBL] [Abstract][Full Text] [Related]
24. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA; Ranson M; Michael M; Olver I; Levitt NC; Mortimer P; Watson AJ; Margison GP; Midgley R; Middleton MR
Br J Cancer; 2008 May; 98(10):1614-8. PubMed ID: 18475294
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
[TBL] [Abstract][Full Text] [Related]
28. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
29. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Rudek MA; Donehower RC; Statkevich P; Batra VK; Cutler DL; Baker SD
Pharmacotherapy; 2004 Jan; 24(1):16-25. PubMed ID: 14740784
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Barvaux VA; Lorigan P; Ranson M; Gillum AM; McElhinney RS; McMurry TB; Margison GP
Mol Cancer Ther; 2004 Oct; 3(10):1215-20. PubMed ID: 15486188
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
Clemons M; Ranson M; Margison JM; El Teraifi H; Griffiths A; Kelly J; Morris CQ; Howell A; Margison GP
Int J Cancer; 2003 Feb; 103(5):686-92. PubMed ID: 12494480
[TBL] [Abstract][Full Text] [Related]
33. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Clemons M; Kelly J; Watson AJ; Howell A; McElhinney RS; McMurry TB; Margison GP
Br J Cancer; 2005 Nov; 93(10):1152-6. PubMed ID: 16278661
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Kefford RF; Thomas NP; Corrie PG; Palmer C; Abdi E; Kotasek D; Beith J; Ranson M; Mortimer P; Watson AJ; Margison GP; Middleton MR
Br J Cancer; 2009 Apr; 100(8):1245-9. PubMed ID: 19367282
[TBL] [Abstract][Full Text] [Related]
35. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
Watson AJ; Sabharwal A; Thorncroft M; McGown G; Kerr R; Bojanic S; Soonawalla Z; King A; Miller A; Waller S; Leung H; Margison GP; Middleton MR
Clin Cancer Res; 2010 Jan; 16(2):743-9. PubMed ID: 20068091
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Rizzieri D; LoRusso S; Tse W; Khan K; Advani A; Moore J; Karsten V; Cahill A; Gerson SL
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):211-6. PubMed ID: 20511167
[TBL] [Abstract][Full Text] [Related]
37. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Ueno T; Ko SH; Grubbs E; Yoshimoto Y; Augustine C; Abdel-Wahab Z; Cheng TY; Abdel-Wahab OI; Pruitt SK; Friedman HS; Tyler DS
Mol Cancer Ther; 2006 Mar; 5(3):732-8. PubMed ID: 16546988
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Plummer R; Jones C; Middleton M; Wilson R; Evans J; Olsen A; Curtin N; Boddy A; McHugh P; Newell D; Harris A; Johnson P; Steinfeldt H; Dewji R; Wang D; Robson L; Calvert H
Clin Cancer Res; 2008 Dec; 14(23):7917-23. PubMed ID: 19047122
[TBL] [Abstract][Full Text] [Related]
40. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
